State of the Science Summit Recaps | Supplements and Featured Publications
Newly Approved ADCs Expand Options in HR+ Metastatic Breast Cancer
April 03, 2025
Article
Sara Nunnery, MD, MSCI, discusses the impact of the approvals of T-DXd and Dato-DXd in HR-positive breast cancer and sequencing questions with ADCs.
Blinatumomab Consolidation Prevents B-ALL Relapses and CAR T-Cell Therapy Consolidation May, Too
March 26, 2025
Article
Gregory Roloff, MD, details data on consolidation therapy with blinatumomab or CAR T-cell therapy for B-ALL, and the role of these agents in this setting.
KRAS G12C and Beyond: KRAS Targeted Agents of Interest Under Development in NSCLC
March 25, 2025
Article
Benjamin Herzberg, MD, highlights novel therapies in the KRAS-mutated NSCLC landscape and ongoing questions research is seeking to answer in this space.
Divarasib Looks to Best Sotorasib/Adagrasib and Solidify a Role in KRAS G12C-Mutated NSCLC
March 24, 2025
Article
Benjamin Herzberg, MD, details research in KRAS G12C-mutated NSCLC with divarasib and how he currently selects between available therapies in this space.
PARP Inhibitor and ARPI Combinations Are at the Forefront of Investigations in mCRPC
March 20, 2025
Article
Monica Chatwal, MD, details new research shedding light on PARP/ARPI combinations in mCRPC, especially in BRCA-mutated and HRR gene–altered populations.
Data Continue to Reshape Treatment Considerations Across Advanced GI Malignancies
February 25, 2025
Article
Mohammed Najeeb Al Hallak, MD, MS explores treatment considerations in advanced pancreatic, colorectal, and neuroendocrine cancers.
Updated Clinical Trial Data Reflect Efforts to Optimize IO Combos in Non-ccRCC and MIBC, Fine-Tune ADT-Based Regimens in Prostate Cancer
February 25, 2025
Article
Pedro Barata, MD, provides insights on key updates in RCC, MIBC, and prostate cancer, as discussed during a State of the Science Summit™.
Radioligand Therapies and Emerging Targets Drive Innovation in Prostate Cancer Management
February 24, 2025
Article
Pedro Barata, MD, discusses the expansion of radioligand therapies and the identification of novel targets beyond PSMA in prostate cancer.
Frontline Therapy Selection in HCC Hinges on Bleeding Risk and Patient-Specific Factors
February 21, 2025
Article
Mohammed Najeeb Al Hallak, MD, MS, discusses patient-specific factors to consider during the selection of frontline systemic therapy for HCC.
Key HCC Trial Data Establish the Role of Later-Line Cabozantinib and Raise Further Frontline Questions
February 20, 2025
Article
Gentry King, MD, discusses positive and negative outcomes following the phase 3 CELESTIAL and COSMIC-312 trials in patients with hepatocellular carcinoma.
Immune Checkpoint Inhibitors Retain Their Role in the HCC Treatment Paradigm
February 19, 2025
Article
Gentry King, MD, highlights the evolution of treatments in the hepatocellular carcinoma landscape and the impact of the phase 3 HIMALAYA trial.
Novel Agents May Enhance JAK Inhibitor Efficacy and Augment the Myelofibrosis Treatment Paradigm
January 10, 2025
Article
Naseema Gangat, MBBS, discusses clinical factors that she uses to choose the optimal JAK inhibitors for individual patients with myelofibrosis.
NGS and Novel Therapies Lends to Prolonged Survival Outcomes in HR+/ HER2– Breast Cancer
December 04, 2024
Article
Francisco J. Esteva, MD, PhD, discusses how NGS sequencing, PIK3CA-targeted therapies, and ADCs are reshaping treatment in HR+/HER2– breast cancer.
Long-Term Findings Solidify Role of HER2-Targeted Therapy in Early HER2+ Breast Cancer
November 22, 2024
Article
Francisco J. Esteva, MD, PhD, highlights various pivotal studies for the treatment of HER2-positive early-stage breast cancer.
Ongoing and Planned Research Build on Prior Advancements in ER+/HER2– Breast Cancer
November 19, 2024
Article
Lubna Naaz Chaudhary, MD, MS, highlights the PARSIFAL and Young-PEARL trials and discusses ongoing research in ER-positive/HER2-negative breast cancer.
Data Continue to Help Shape CDK4/6 Inhibitor Selection, Sequencing in HR+ Breast Cancer
November 18, 2024
Article
Lubna Naaz Chaudhary, MD, MS, discusses selecting a CDK4/6 inhibitor in hormone receptor–positive breast cancer.
Molecular Testing Helps First-Line Treatment Landscape Evolve in Pancreatic Cancer
November 17, 2024
Article
Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.
Refined Definition of Platinum Resistance, Novel ADCs Could Bring More Changes to Ovarian Cancer Treatment
November 12, 2024
Article
Kathleen N. Moore, MD, MS, discusses the evolving treatment landscape of platinum-resistant ovarian cancer.
Genomic Predictors Inform the Evolving Role of Chemotherapy in Breast Cancer Management
November 12, 2024
Article
Kari Wisinski, MD, highlights treatments for HER2– breast cancer, the role of chemotherapy in TNBC, and the benefits of T-DXd for brain metastases.
AE Profiles and Dosing Schedules Define the Role of CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer
November 07, 2024
Article
Kari Wisinski, MD, discusses factors that influence her decision between CDK4/6 inhibitors for patients with treatment-naive, HR+ metastatic breast cancer.